An assessment of the effects of altering blood pressure on cerebral and systemic haemodynamics in patients with acute ischaemic stroke

Submission date 25/08/2005	Recruitment status Stopped	Prospectively registeredProtocol
Registration date	Overall study status	Statistical analysis plan
28/10/2005	Stopped	☐ Results
Last Edited	Condition category	☐ Individual participant data
03/03/2016	Circulatory System	☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Philip Bath

Contact details

Division of Stroke Medicine Clinical Sciences Building City Hospital Campus Hucknall Road Nottingham United Kingdom NG5 1PB +44 (0)115 840 4792 philip.bath@nottingham.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

An assessment of the effects of altering blood pressure on cerebral and systemic haemodynamics in patients with acute ischaemic stroke

Study objectives

To assess the effects of altering blood pressure on cerebral and systemic haemodynamics in patients with acute ischaemic stroke.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Ischaemic Stroke

Interventions

Patients will be randomised to receive intravenous dobutamine or normal saline alone. Dobutamine will be administered at increasing concentrations at 5 minute intervals. Measurements using transcranial doppler, pulse wave analysis and venous blood samples will be taken at baseline and at each 5 minute dose increment.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Dobutamine

Primary outcome measure

- 1. The ability of dobutamine to reduce systolic, diastolic and mean arterial BP
- 2. Safety and tolerability of dobutamine in acute ischaemic stroke.

Secondary outcome measures

90 day modified Rankin, Barthel and mortality.

Overall study start date

01/01/2000

Completion date

01/01/2007

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

- 1. Patients of either sex ≥18 years
- 2. Proven ischaemic stroke on computed tomography (CT)
- 3. Stroke onset within 96 hours
- 4. Written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

24

Key exclusion criteria

- 1. Non-ischaemic stroke
- 2. Unconscious or Scandinavian Neurological Stroke Scale (SNSS) conscious level <4

- 3. Baseline systolic blood pressure (BP) >180 mmHg or <100 mmHg
- 4. Baseline diastolic BP >110 mmHg or <60 mmHg
- 5. Women of childbearing potential/pregnant/lactating

Date of first enrolment

01/01/2000

Date of final enrolment

01/01/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Division of Stroke Medicine

Nottingham United Kingdom NG5 1PB

Sponsor information

Organisation

University of Nottingham

Sponsor details

Clinical Sciences Building
City Hospital Campus
Hucknall Road
Nottingham
England
United Kingdom
NG5 1PB
+44 (0)115 840 4791
phillip.bath@nottingham.ac.uk

Sponsor type

University/education

ROR

https://ror.org/01ee9ar58

Funder(s)

Funder type

University/education

Funder Name

University of Nottingham

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration